InvestmentPitch Media video shows LOVE Pharma signing a non-binding LOI to acquire 100% of Naltrexone Therapeutics Inc., a pharmaceutical technology company with significant IP related to the FDA-approved transdermal delivery of naltrexone is explained.

VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) — LOVE Pharma (CSE:LUV) (FSE:G1Q0) has binding power to acquire 100% of pharmaceutical technology company Naltrexone Therapeutics Inc. signed a basic agreement without It holds significant intellectual property related to the FDA-approved transdermal delivery of naltrexone. Naltrexone is an opioid antagonist and is used primarily to manage alcohol and opioid use disorders by reducing the cravings and euphoria associated with substance abuse disorders.

Media snippets accompanying this announcement are available by clicking the image or link below.

For more information, watch the InvestmentPitch Media video that provides additional information about this news and the company. You can watch the video at “”.investment pitch“When”Youtube”. If these links are not enabled, please visit the following URLs: www.InvestmentPitch.com Type “Love Pharma” in the search box.

Transdermal delivery of naltrexone is expected to modulate dosage, reduce gastrointestinal-related side effects, and improve the overall patient experience. Most importantly, transdermal delivery of naltrexone may eliminate or reduce the side effects of current drugs such as nausea that may limit the growth of the existing naltrexone market.

Zak Stadnik, President and CEO, said:Love Pharma is very excited to add the Naltrexone Therapeutics transdermal patch IP to its addiction treatment portfolio. Transdermal delivery provides patients with convenient and safe naltrexone therapy, increases bioavailability, provides consistent absorption, and reduces gastrointestinal-related side effects common with currently available oral administrations. We believe the latter has the potential to expand the market for naltrexone.”

Transdermal formulations of drugs can be incorporated into patches that are applied to the patient’s skin surface, thereby providing a consistent rate of absorption over the prescribed prescribed time. The delivery method for transdermal delivery of suitable drugs is very flexible and can be designed to release drug for various times ranging from 24 hours to over 144 hours and even longer days.

The drug addiction treatment market is projected to exceed US$31 billion by 2027.

Zak Stadnik, President and CEO, added:With multiple patient-centric benefits and best-in-class relationships with biotechnology laboratories dedicated to rapidly tracking the development, approval and launch of transdermal drug delivery systems, Love Pharma is positioned in the addiction space. has produced strong papers on transdermal drug delivery applications.Explore new markets and applications for existing FDA-approved drugs”

Consideration totaling C$2,000,000 will be paid in common stock and is expected to be completed within 30 days, subject to definitive due diligence. Details will be announced upon signing of the formal contract.

Focused on the global sexual health and wellness market, Love Pharma was founded in 2020 with the goal of bringing to market innovative products that enhance sexual health and wellness while improving quality of life. I have a mission. Love Pharma holds exclusive licenses to manufacture, package, market and distribute patented therapeutics and pharmaceuticals in Europe, the United Kingdom and North America.

The company is well-funded, having recently raised over $2 million and its shares are currently trading at $0.015.

For more information, please visit the company’s website. www.love-pharma.complease contact Zach Stadnyk, CEO, by phone at 604-343-2977 or by email. [email protected].

Disclaimer

The information in this Investmentpitch Media Ltd video is for viewer information. Love Pharma paid him no more than $2,000 in cash to produce the current news release in video format. Company information is based on publicly available information. Information provided by Investmentpitch Media Ltd. through its media services is not to be construed as a recommendation, offer or offer to buy or sell securities and is provided solely as an information media service. Investmentpitch Media Ltd makes no warranties or promises as to the accuracy or completeness of this information. All due diligence must be done by the viewer or their financial advisor. Investing in securities is speculative and involves risk.

About Investment Pitch Media

Investment Pitch Media harnesses the power of video, combined with its wide distribution, to put your company’s story ahead of thousands seeking recognition and funding from the financial industry. The company specializes in producing short videos based on important news releases, research reports and other content of interest to investors.

CBJ Newsmaker